XML 13 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Comprehensive Income - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
 [2]
Statement of comprehensive income [abstract]    
Net income [1] € 5,837 € 2,263
Attributable to equity holders of Sanofi [1] 5,812 2,246
Attributable to non-controlling interests [1] 25 17
Other comprehensive income:    
Actuarial gains/(losses) [1] 111 235
Change in fair value of equity instruments included in financial assets and financial liabilities [1] 222 (10)
Tax effects [1] (92) (59)
Items not subsequently reclassifiable to profit or loss from continuing operations [1] 241 166
Change in fair value of debt instruments included in financial assets [1] 3 (5)
Change in fair value of cash flow hedges [1] (23) (3)
Change in currency translation differences [1] (5,203) 1,040
Tax effects [1] (95) 35
Items subsequently reclassifiable to profit or loss [1] (5,318) 1,067
 Other comprehensive income/(loss) from continuing operations for the period, net of taxes (A+B) [1] (5,077) 1,233
 Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C) [1] 303 (23)
Comprehensive income [1] 1,063 3,496
Attributable to equity holders of Sanofi [1] 1,076 3,471
Comprehensive income, attributable to owners of parent, continuing operations [1] (2,097) 3,264
Comprehensive income, attributable to owners of parent, discontinued operations [1] 3,173 207
Attributable to non-controlling interests [1] € (13) € 25
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.